Clinical Trial to Evaluate the Efficacy of Intracavernosal Infusion of PRP vs PPP for the Erectile Dysfunction.

Inclusion Criteria: * Signed an ethics committee-reviewed and approved informed consent form. * Subjects must meet all inclusion criteria to be eligible for study enrollment. * Men between 40 and 75 years old, with a relationship of more than 6 months of duration. * Erectile dysfunction for at least 6 months with an IIEF-EF (while using the higher tolerated dose of PDE5-Is) between 5 and 16 points, inclusive. * Erectile dysfunction of vascular origin. In case of clinical doubt or incongruence, a Nocturnal Penile Tumescence and Rigidity Test (NPTR) will be performed. In this case, criteria inclusion is having no event in the night with a penile rigidity (tip) of ≥70% during ≥5min. * Subjects agree to attempt vaginal intercourse at least 4 times every month after the end of the treatment and agree to document the outcome using the Sexual Encounter Profile (SEP) and the Erection Hardness Score (EHS). * Commitment not to use other treatment for ED during the study (herbal, topical, intraurethral, intracavernosal, etc.). * Commitment to completing the rest of the questionnaires and other measurement instruments during the study phase. * Willingness and ability to comply with study procedures, other measurements instruments and visit schedules and able to follow oral and written instructions. Exclusion Criteria: * Documented psychogenic erectile dysfunction (with NPTR test: at least one event in the night with a penile rigidity (tip) of ≥70% during ≥5min). * Erectile dysfunction of neurogenic origin (radical prostatectomy, pelvic surgery, spinal cord injury, multiple sclerosis, diabetes mellitus is not included unless documented diabetic neuropathy). * Some other current sexual dysfunction (premature ejaculation, etc.). * Prior implant of penile prosthesis or other penile surgeries different to circumcision, frenuloplasty or condyloma removal. * Previous history of penile fracture, Peyronie's disease or priapism. * History of radical prostatic or bladder surgery (radical cystectomy or prostatectomy). * Previous radiation to pelvis. * History of symptomatic hypogonadism (testosterone level \<346ng/dl) not treated. If treated hypogonadism, testosterone levels non-stable for at least 3 months. * Major hematologic, renal, or hepatic abnormalities. * Severe decompensated cardiac and vascular insufficiency, or critical coronary heart disease. * Poorly controlled hypertension or diabetes mellitus (HbA1c \>12%). * Recent (within previous six months of the inclusion) stroke or myocardial infarction. * Active peptic ulcer disease. * Neoplasm of any origin in active treatment or active progression. * History of psychiatric pathology (depressive syndrome, schizophrenia, bipolar disorder). * History of alcohol abuse (More than 7 alcohol drink units a week or more than 3 per occasion) or drug abuse (any drug consumption different to alcohol or tobacco, used more than three times per month). * Treatment with oral anticoagulants (dicoumarin or by-products) or antiandrogens. * Active treatment as nitric oxide (NO) donor drugs. * Prior positive serology to HBsAg, HCV (by genomic test), HIV-1/2, syphilis. * Thrombopenia less than 100 x 109 / L. * Anemia (Hemoglobin \<13 g/dl). * Poor venous access or any other circumstance that preclude an apheresis procedure. * Lack of sexual practices in recent months (less than 4 attempts in the last three months). * Lack of commitment on the part of the patient to attend the tests requested.